Atlas Trials

Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

Clinical trial NCT07379827 · RECRUITING

Trial details

NCT number
NCT07379827
Sponsor
Bristol-Myers Squibb
Status
RECRUITING
Study type
OBSERVATIONAL
Schizophrenia
Start date
2026-02-26
Primary completion
2028-06-20
Enrollment
1500

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.